Ultralong CDR3 Immunoglobulin Constructs for Antibody Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody technologies face limitations in utilizing ultralong CDR3 sequences for therapeutic applications due to challenges in producing and integrating these sequences into functional antibodies, particularly in terms of cysteine content and structural diversity.
Innovation Solution
Development of immunoglobulin constructs comprising ultralong CDR3 sequences with 35 or more amino acids, incorporating cysteine motifs and additional sequences like cytokines, linked via specific linkers, to enhance binding capabilities and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ultralong CDR3 sequences (35+ amino acids) are incorporated into immunoglobulin constructs, then antigen binding specificity and therapeutic efficacy are improved, but structural stability and ease of manufacture deteriorate due to challenges in integrating these sequences into functional antibodies
Solution Approach 1:
The ultralong CDR3 sequence is divided into multiple segments or domains (e.g., N-terminal domain, central domain, C-terminal domain) that can be independently designed and assembled. This segmentation allows each domain to be optimized for specific functions (binding, stability, flexibility) while simplifying the overall integration process into the immunoglobulin construct
Solution Approach 2:
Linker sequences are introduced as intermediary elements between the CDR3 sequence and the rest of the antibody framework. These linkers serve as flexible connectors that facilitate proper folding and integration of the ultralong CDR3 while maintaining structural stability and ease of manufacturing
2Adaptability or versatility
If multiple cysteine residues are included in ultralong CDR3 sequences, then structural diversity and binding capabilities are enhanced, but production challenges and structural complexity increase
Solution Approach 1:
Cysteine residues are strategically positioned at specific locations within the ultralong CDR3 sequence rather than distributed uniformly. This local placement allows cysteines to form specific disulfide bonds that stabilize particular structural motifs (such as knobs or stems) while maintaining overall structural diversity and binding capabilities without excessive complexity
Solution Approach 2:
The ultralong CDR3 sequence is designed as a composite structure combining cysteine-rich domains with cysteine-poor regions. This composite approach allows the cysteine-containing segments to provide structural diversity and binding versatility, while the other regions maintain simplicity and ease of production
3Reliability
If ultralong CDR3 sequences are used in immunoglobulin constructs, then therapeutic potential is enhanced, but production and integration challenges arise
Solution Approach 1:
The ultralong CDR3 sequence is pre-validated and optimized in isolation or in simplified model constructs before being integrated into full immunoglobulin molecules. This preliminary action allows the sequence to be tested for stability, folding, and binding properties, ensuring therapeutic potential is maximized while identifying and resolving production challenges before full-scale manufacturing
Data Source
AI summary
Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.